Ingevity (NGVT) Q2 2024 earnings summary

Executive summary

• Q2 2024 net sales were $390.6 million, down 19% year-over-year, mainly due to repositioning in Performance Chemicals and reduced industrial demand, while Performance Materials achieved its fourth consecutive quarter of 50%+ EBITDA margins and Advanced Polymer Technologies posted its third straight quarter of volume growth despite lower pricing.

• Net loss for Q2 2024 was $283.7 million, primarily due to a $349.1 million non-cash goodwill impairment charge in Performance Chemicals, with significant restructuring charges and operational cost savings expected through 2025.

• Major repositioning actions included terminating a costly long-term CTO supply contract, closing the Crossett, Arkansas facility, and consolidating oleo refining to North Charleston, expected to yield $30–$35 million in annual savings starting 2025.

Financial highlights

• Q2 2024 adjusted EBITDA was $101.3 million (25.9% margin), down 16% year-over-year, with gross profit of $123.2 million and gross margin of 31.5%.

• Free cash flow was $12 million, negatively impacted by $26 million in CTO resale losses and $13 million in restructuring charges.

• Diluted adjusted EPS was $1.01, down 28% from Q2 2023; no share repurchases in Q2, with $353.4 million remaining under authorization.

Outlook and guidance

• Full-year 2024 sales guidance revised to $1.4–$1.5 billion; adjusted EBITDA guidance set at $350–$360 million; CAPEX expected at $90–$100 million.

• Free cash flow guidance updated from >$75 million to slightly positive, reflecting $100 million CTO contract termination fee and $10 million in severance costs.

• Performance Chemicals segment expected to remain challenged through Q1 2025, with improvement anticipated from Q2 2025 as cost structure improves and high-cost CTO inventory is worked through.